CD40 antagonist or CD154 antagonist for use in mitigating immune responses in protein and gene therapies
By administering CD40 or CD154 antagonists to block the CD40-CD154 co-stimulatory pathway, the immune responses against therapeutic agents in PRT and gene therapy are mitigated, enabling effective and repeated administration of therapeutic proteins and vectors.
Patent Information
- Application Number
- PCT/IB2025/051326
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-02-09
- Filing Date
- 2025-02-07
- Publication Date
- 2025-08-14
AI Technical Summary
Protein replacement therapy (PRT) and gene therapy often face immune responses, such as T cell-dependent antibody responses and T-cell-mediated cytotoxicity, leading to reduced efficacy of therapeutic agents due to neutralizing antibodies and increased clearance, necessitating methods to mitigate these immune reactions.
Administration of a pharmaceutical composition containing a CD40 antagonist or a CD154 antagonist, such as anti-CD40 antibodies or antigen-binding fragments, to block the CD40-CD154 co-stimulatory pathway, thereby reducing immune responses and enhancing the efficacy of PRT and gene therapy.
The use of CD40 or CD154 antagonists inhibits neutralizing antibody development and T-cell cytotoxicity, allowing repeated administration of therapeutic agents without adverse immunogenic reactions, thus improving the efficacy of PRT and gene therapy.